PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “NEW ZEALAND”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources

Bone marrow transplantation in New Zealand. New Zealand Bone Marrow Transplant Study Group.

From their initiation in 1979 until the end of 1992, five New Zealand transplant centres have carried out a total of 233 bone marrow transplants, of which 149 were allografts and 84 autografts. The New Zealand Bone Marrow Transplant Study Group aims to coordinate the transplant programmes and maintains a collaborative register of transplants. This report provides a brief overview of transplantation activity within New Zealand and summarises the results.

Anemia, Aplastic↗

Cardiovascular Drug Access in Australia and New Zealand: New PBS and PHARMAC Listings, 2023-2025.

BACKGROUND: Cardiovascular disease is a leading cause of death in Australia and New Zealand. Publicly subsidised access to new cardiovascular medications is governed by the PBS (Pharmaceutical Benefits Scheme) in Australia and PHARMAC (Pharmaceutical Management Agency) in New Zealand, yet no consolidated resource catalogues recent listings across both jurisdictions. METHODS: We reviewed all new cardiovascular drug listings and indications on the PBS and PHARMAC schedules from 1 January 2023 to 31 December 2025. PBS data were obtained from the PBS Pricing and Policy Branch through the Cardiac Society for Australia and New Zealand. PHARMAC data were obtained via direct communication with PHARMAC and cross-referenced with public schedule information. Pivotal trial evidence, restriction criteria, and prescribing considerations were extracted from published literature and regulatory documents. RESULTS: Five new cardiovascular drugs were PBS-listed (inclisiran, mavacamten, tafamidis, icosapent ethyl and migalastat), two existing drugs received new cardiovascular indications (empagliflozin and dapagliflozin for heart failure with preserved ejection fraction) and prasugrel was relisted for acute coronary syndrome. One major change occurred on the PHARMAC schedule (empagliflozin for heart failure with reduced ejection fraction). CONCLUSIONS: The 2023-2025 period has seen notable additions to cardiovascular pharmacotherapy in Australia, including the first cardiac myosin inhibitor, the first transthyretin stabiliser, expanded lipid lowering therapy options, and extension of SGLT2 inhibitor coverage across the heart failure ejection fraction spectrum. A pronounced access disparity persists between Australia and New Zealand.

New Zealand↗

B cell infiltration of the thymic medulla in New Zealand black, New Zealand white, and (New Zealand black x New Zealand white)F1 mice. Effect of total lymphoid irradiation.

Thymuses from female (New Zealand black x New Zealand white)F1 [( NZB x NZW]F1), New Zealand black, and New Zealand white mice of different ages were examined by immunohistochemical and flow cytometric analysis. Two-and-a-half-month-old (NZB x NZW)F1 mice showed infiltration of the thymus with B cells, and by 6-8 months of age, showed a disruption of the entire medullary area. More than 80% of the thymic B cells had the phenotypic characteristics of conventional B cells (IgM+, IgD+, Ly-1-). Total lymphoid irradiation induced a marked depletion of medullary B cells and a restoration of the thymic architecture.

Animals↗

Resting B cells from autoimmune lupus-prone New Zealand Black and (New Zealand Black x New Zealand White)F1 mice are hyper-responsive to T cell-derived stimuli.

To determine whether B cells from New Zealand Black (NZB) and (New Zealand Black x New Zealand White)F1 (NZB/W) mice possess intrinsic defects that lead to altered immune responsiveness, we purified resting B cells from these mice and compared their surface phenotype and function with those of resting B cells isolated from BALB/c and DBA/2 nonautoimmune mouse strains. Flow cytometric analysis of freshly isolated resting B cells revealed that NZB and NZB/W resting B cells are conventional B2-type cells similar to their nonautoimmune counterparts. Despite this, resting B cells from young NZB and NZB/W mice express lower levels of CD23 on their surface and aberrant levels of intracellular IgM. Upon stimulation, resting B cells from young NZB and NZB/W mice demonstrate increased proliferation, IgM secretion, or enhanced expression of costimulatory molecules in response to a variety of different T cell-derived stimuli, including cytokines and signals generated through CD40. Therefore, B cell hyper-responsiveness to T cell stimuli is immunodominant or codominant in NZB/W mice. Taken together, our results suggest that intrinsic B cell hyper-responsiveness may play a role in the pathogenesis of autoimmune disease in NZB and NZB/W mice. The increased clonal expansion of these B cells together with increased Ig production and enhanced costimulatory capacity serve to amplify the immune response. In the context of normal but incomplete T cell tolerance, B cell hyperresponsiveness to the limited signals provided by partially tolerant T cells may be sufficient to yield an autoantibody response.

Animals↗

Factors associated with the age of introduction of solids into the diet of New Zealand infants. New Zealand Cot Death Study Group.

OBJECTIVE: To describe the current timing of the introduction of solids in infancy and the factors influencing the decision to introduce solids. METHODOLOGY: Eighteen hundred infants were selected randomly as part of the New Zealand Cot Death Study. Of these, 88% of the parent/caregivers were interviewed when their infant was aged between 1 and 12 months. They were asked when solids were first introduced into the diet. RESULTS: By 12 weeks of age more than 20% of infants had been given solids; by 16 weeks and by 6 months 50 and 90% of babies, respectively, had been given solids. Maternal smoking, low educational achievement and not being breast-fed exclusively to 4 weeks of age were factors which were strongly associated with the early introduction of solids. CONCLUSION: Half of New Zealand infants are being started on solids earlier than is presently recommended. More education is needed to promote the later introduction of solid foods into the diet.

Age Factors↗

Cost containment: the Pacific. New Zealand.

New Zealand is a small nation with an extensive state-funded system of health, education, and welfare that is currently under "reform." The healthcare system remains largely government-funded and is free to all New Zealand residents. Healthcare spending accounts for approximately 7.4% of the country's gross domestic product and has not changed in the last 5 yrs. Ninety-three percent of New Zealand's ICUs are in public hospitals, where ICU beds constitute 0.9% of the total number of beds. In all, there are 43 ICU beds/1 million inhabitants. Between 1989 and 1992, the number of public hospital beds decreased by 19% and the number of ICU beds decreased by 5%. ICU Resources have been limited for many years, and clinicians have responded by attempting to prevent disease and limit its severity, by vetting (and declining) requests for ICU admission, by reducing length of ICU stay of both survivors and nonsurvivors, and by reducing marginal costs. Both limiting and actively withdrawing therapy are well established practices in New Zealand ICUs. The country's physicians are conservative in their use of new technology but demand excellence and value in equipment. ICU technology and knowledge diffuse easily throughout New Zealand because of the country's geography and population distribution, in addition to the activities of the Australian and New Zealand Intensive Care Society (ANZICS) and the defined specialty training pathways for intensive care. Hospital care is relatively cheap and nurse extenders, respiratory therapists, and ward pharmacists are not used. Flow charts in the ICU are custom-designed and not computerized, but computers are increasingly being used for clinical databases and ICU policy development.

Cost Control↗

The regionality of campylobacteriosis seasonality in New Zealand.

New Zealand has one of the highest incidences of campylobacteriosis in the developed world, which leads a global trend of increasing notifications of Campylobacter infections over the last decade. Foodborne and waterborne transmission have been implicated as significant mechanisms in the complex ecology of the disease in New Zealand. We examined both regional and temporal variation in notification rates to gain some insight into the role of the New Zealand environments in modifying disease incidence. Firstly, there is a marked difference in the seasonality of campylobacteriosis between the North and South Islands of New Zealand. The Far North and much of the rural North Island were found to display relatively low summer incidence and small inter-seasonal variation. Secondly, there appears to be a dispersed grouping of North Island urban areas, including Auckland, Hamilton, Napier and their hinterlands as well as a few areas on the South Island that exhibit higher summer incidence and more seasonality than the first group. Thirdly, Christchurch, Dunedin, much of the South Island and the lower North Island cities of Wellington and Upper Hutt appear to experience the highest summer incidence and strongest inter-seasonal variation in New Zealand. These three broad groupings of campylobacteriosis seasonality, constructed using a principal components analysis, suggest that the importance of transmission routes may vary regionally in New Zealand. The observed variation in seasonal incidence indicates a complex ecology that is unlikely to be explained by a single dominant transmission route across these three groupings.

Campylobacter Infections↗

Tolerance defects in New Zealand Black and New Zealand Black X New Zealand White F1 mice.

The susceptibility of autoimmune NZB and (NZB X NZW)F1 mice to the induction of tolerance by monomeric BSA was compared with several normal mouse strains. Unresponsiveness in T and B lymphocyte compartments was probed by challenging with DNP8BSA and measuring anti-DNP and anti-BSA antibodies separately. Tolerance induced by monomeric BSA was carrier specific, and there was no evidence of epitope-specific suppression. Normal NZW, NFS, and B10.D2 mice were easily rendered tolerant with monomeric BSA and did not produce anti-DNP or anti-BSA antibodies after challenge with DNP8BSA. By contrast, the lack of anti-DNP antibody response in similarly treated NZB mice was dependent on the dose of monomeric BSA, indicating that the helper T cells were partially resistant to tolerance induction. NZB mice treated with a high dose of monomeric BSA produced anti-BSA, but not anti-DNP, antibodies after immunization. Thus, the anti-carrier B cells in NZB mice may have been primed by monomeric BSA. The presence of the xid gene on the NZB background rendered the mice susceptible to induction of tolerance, suggesting that the tolerance defect in NZB mice involves the B cell compartment. This abnormal antibody response was a dominant trait: (NZB X NFS)F1 and (NZB X B10.D2)F1 mice had the same characteristics as NZB mice. These F1 hybrids do not develop autoimmune disease, indicating that resistance to experimental tolerance induction expressed at a B cell level may not be sufficient for disease development. In contrast to NZB and other NZB F1 hybrids, (NZB X NZW)F1 hybrids treated with monomeric BSA and challenged with DNP8BSA responded to both DNP and BSA. The contribution of a B cell defect to the tolerance abnormality of (NZB X NZW)F1 mice was examined by analyzing the effect of the xid gene on the progeny of (NZB.xid X NZW)F1 mice. Unlike the effect of the xid gene on NZB mice, both phenotypically normal heterozygous female and phenotypically xid hemizygous male mice produced anti-DNP and anti-BSA antibodies after tolerance induction and immunization, demonstrating that a major helper T cell abnormality was present in (NZB X NZW)F1 mice. The (NZW X B10.D2)F1 hybrid was rendered tolerant by this procedure, indicating that the helper T cell defect (NZB X NZW)F1 mice may have resulted from gene complementation with the NZB mice contributing partial resistance of T helper cells to tolerance induction.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗

Risk factors for small for gestational age infants: a New Zealand study. New Zealand Cot Death Study Group.

AIM: The aim was to identify risk factors for small for gestational age infants. METHOD: Case-control study. The study population was 1800 infants selected randomly from all babies born over a three year period over 78% of the country. Of these 1800 infants, 85 (4.8%) were classified as preterm (< 37 weeks completed gestation) and were excluded. 157 (8.9%) were classified as small for gestational age (cases) and 1519 (86.3%) were fullterm, nonsmall for gestational age infants (controls). Risk factors were investigated using data collected from obstetric records and parental interviews. RESULTS: Risk factors associated with small for gestational age after controlling for potential confounders included maternal smoking during pregnancy (Odds ratio (OR) 2.61, 95% confidence interval (CI) 1.65, 4.15), primiparity (OR 2.96, 95% CI 1.59, 5.48), lack of antenatal care in the first trimester (OR 1.83, 95% CI 1.13, 2.98) and young age when mother left school (OR 1.56, 95% CI 1.01, 2.41). Use of marijuana in pregnancy significantly increased risk of small for gestational age at the 6% level (OR = 1.86, 95% CI 0.98, 3.52). The population attributable risk for maternal smoking was 31.1% (95% CI 18.2, 41.9). CONCLUSION: Maternal smoking was the most important modifiable risk factor in this dataset for small for gestational age.

Adolescent↗

Selenium in human nutrition in New Zealand.

New Zealand's soil has a low concentration of selenium (Se), and its residents have a lower Se status than do most other peoples. However, New Zealanders do not suffer from the Se-responsive ills that afflict their farm animals and some people in China. New Zealanders, particularly those in the South Island, may have adapted to their low Se environment by thriftiness in urinary excretion of Se. Low glutathione peroxidase activities in their tissues have not resulted in noticeable damage or changes. The enzyme activity can be raised to a plateau by Se supplements, but there is no evidence that supplementation leads to better health. Since patterns of coronary heart disease, hypertension, and cancer in New Zealand resemble those in other Western countries, no direct link between these diseases and Se level is likely.

Humans↗

Maternal mortality in New Zealand.

New Zealand's maternal mortality rate in the triennium 1986-8 was reviewed in comparison with the rates from Australia and the United Kingdom during 1985-7. The New Zealand rate of 9.6 obstetric deaths/100,000 total births was higher than that for the United Kingdom (6.2) and Australia (4.4). Six of 16 deaths in New Zealand during the triennium were caused by sepsis, including five cases of puerperal infection with group A beta-haemolytic streptococci. Careful analysis of maternal deaths in New Zealand remains an important priority to provide audit of the performance of maternity services.

Australia↗

The epidemiology of diabetes and its complications in New Zealand.

New Zealand is a country in the South Pacific with a high proportion of Polynesians. While the prevalence of diabetes appears the same in New Zealand Europeans as Europeans elsewhere, Maori and Pacific Islands people have a 2 to 4-fold excess prevalence of diabetes. Although Europeans make up the majority of diabetic New Zealanders, the greatest concern lies with the Maori and Pacific Islands patients who experience an earlier age at diagnosis, greater obesity, higher rates of smoking (in Maori), poorer diabetes knowledge, poorer glucose control, and more end stage renal failure and blindness. Efforts are now being made to control the current epidemic.

Cardiovascular Diseases↗

Major colorectal cancer aetiological hypotheses do not explain mortality trends among Maori and non-Maori New Zealanders.

New Zealand colorectal cancer mortality rates are presented for the period 1947-1980. Mortality has been increasing and is now the highest in the world for both males and females in the age range 35-64; indeed New Zealand mortality rates for those aged 35-44 are approximately twice those of other countries with high mortality. By contrast, colorectal cancer mortality rates among Maoris, the indigenous New Zealanders of Polynesian descent, have been decreasing so that they are now less than half the non-Maori mortality rates. These findings cannot be explained by ethnic differences in consumption of the major proposed dietary risk factors: total fat, cholesterol, meat, fibre and beer. Possible differences in the prevalence of lactose malabsorption, in faecal mutagen activity, and in the prevalence of colorectal polyps warrant further investigation.

Adult↗

Holistic nursing in New Zealand.

New Zealand nurses are active and dynamic emerging holistic practitioners. Despite an economic recession and dramatic changes in their health care delivery systems, the country's holistic nurses have mobilized to develop and begin a holistic nurses' association. Holistic nurses from both islands have begun independent practices using complementary therapies and modalities. Although New Zealand is distant from North America geographically, there have been increasing numbers of exchange visits and subsequent influence on international holistic nursing practice. New Zealand, being a lush, green, clean, semitropical country in the South Pacific, is a wonderful place for North American nurses to experience cross-cultural nursing while still being in an English-speaking country.

Holistic Health↗